A Double-Blind, Randomized Phase III Trial: 1% Benvitimod Cream for Mild-to-Moderate Plaque Psoriasis

0
0
0

A Double-Blind, Randomized Phase III Trial: 1% Benvitimod Cream for Mild-to-Moderate Plaque Psoriasis

Psoriasis affects over 125 million people worldwide, with plaque psoriasis—red, scaly patches that often itch or burn—being the most common form. For those with mild-to-moderate disease, topical treatments like corticosteroids or vitamin D analogs (e.g., calcipotriol) are standard. But long-term use of these therapies can lead to side effects: corticosteroids may thin skin or cause discoloration, while vitamin D analogs can trigger irritation. Could a new synthetic cream offer a safer, more effective alternative? A 2020 phase III trial published in the Chinese Medical Journal suggests 1% benvitimod cream might be the answer.

What Is Benvitimod?

Benvitimod (also called tapinarof or GSK2894512) is a novel small molecule originally derived from metabolites of Photorhabdus luminescens, a soil bacterium. Unlike traditional topicals, it targets the aryl hydrocarbon receptor (AhR)—a protein that regulates immune responses and cytokine production, key drivers of psoriasis inflammation. Early phase I and II trials showed benvitimod reduced psoriasis severity without systemic side effects. The phase III trial aimed to confirm these results in a larger, more diverse group.

The Trial Design: Rigorous and Patient-Focused

The study was a double-blind, randomized, placebo- and positive-controlled trial—the gold standard for testing new drugs. Researchers enrolled 686 adults (18–65 years old) with mild-to-moderate plaque psoriasis (lesions covering <10% of their body, and a static Physician’s Global Assessment (sPGA) score of 2 or higher, meaning moderate disease). Participants were split into three groups:

  • 2:1:1 ratio: 344 received 1% benvitimod cream twice daily, 169 used 0.005% calcipotriol ointment (a widely used vitamin D analog), and 173 got a placebo (inactive cream).
  • 12-week treatment: Primary goals were to measure two key outcomes:
    1. PASI 75: A 75% or greater reduction in the Psoriasis Area and Severity Index (PASI), which scores lesion area, redness, thickness, and scaling.
    2. sPGA 0/1: An sPGA score of 0 (clear skin) or 1 (minimal psoriasis), meaning the disease was nearly or completely gone.

After 12 weeks, patients who achieved sPGA 0/1 entered a long-term follow-up (up to 52 weeks) to track recurrence and retreatment efficacy.

Results: Benvitimod Outperforms Placebo and Rival Topicals

The data showed benvitimod was both effective and consistent:

  • PASI 75: 50.4% of benvitimod users reached this critical threshold—significantly higher than calcipotriol (38.5%, P < 0.05) and placebo (13.9%, P < 0.05).
  • sPGA 0/1: 66.3% of benvitimod patients had clear or minimal psoriasis, comparable to calcipotriol (63.9%) and far better than placebo (33.5%, P < 0.05).
  • PASI 90: For patients seeking near-total clearance, benvitimod shined: 32.6% achieved a 90% improvement, vs. 20.1% for calcipotriol and just 3.5% for placebo (P < 0.05).

Long-term follow-up added even more good news: While 50.8% of patients who initially responded to benvitimod experienced recurrence (common in chronic psoriasis), retreatment worked. By week 52, 73.3% regained sPGA 0/1—proof benvitimod can be used repeatedly for flare-ups.

Safety: Mild Side Effects, No Systemic Risk

Benvitimod was well-tolerated overall, though it caused more mild-to-moderate side effects than calcipotriol or placebo. The most common issues were local skin reactions:

  • Pruritus (itching): 21.2% of benvitimod users vs. 10.1% (calcipotriol) and 12.1% (placebo).
  • Contact dermatitis or folliculitis (inflamed hair follicles): More common in the benvitimod group but rarely severe.

All side effects were transient—most resolved without treatment. Crucially, no systemic side effects (e.g., liver or kidney damage, hormonal changes) were reported. Serious adverse events were rare (1.2% in all groups) and mostly unrelated to the drug.

Why This Matters for Psoriasis Patients

This trial is a game-changer for people with mild-to-moderate plaque psoriasis. Here’s why:

  1. Non-steroidal, targeted action: Benvitimod’s AhR targeting avoids the long-term risks of corticosteroids (e.g., skin thinning) while being more effective than vitamin D analogs for many patients.
  2. Repeatable efficacy: Recurrence is common in psoriasis—benvitimod’s ability to work again after flare-ups makes it a practical long-term option.
  3. Safety: No systemic side effects mean fewer worries about hidden health risks.

The Takeaway

For patients tired of the trade-offs with existing topical treatments, benvitimod cream offers a new, evidence-backed choice. The phase III trial confirms it’s more effective than placebo and competitive with calcipotriol—with a safety profile that favors long-term use. As with any drug, individual results may vary, but this study adds strong support for benvitimod as a first-line option for mild-to-moderate plaque psoriasis.

The trial was conducted by researchers from Peking University People’s Hospital, Beijing Wenfeng Tianji Pharma Ltd., and 21 other Chinese medical centers. It was published in the Chinese Medical Journal in 2020 (Lin Cai et al.). The study is registered with the Chinese Clinical Trial Registry (ChiCTR-TRC-13003259).

doi:10.1097/CM9.0000000000001221

Was this helpful?

0 / 0